Teva

Aug 08, 2018

Teva’s migraine drug is expected to launch this year despite the delay in FDA approval Teva Pharmaceutical’s fremanezumab for treating migraine is expected to launch later this year.  Celltrion disclosed that U.S. drug regulators issued a Form 483 for its plant in Incheon, South Korea on tuesdsy. Eight manufacturin...

Nov 07, 2017

Teva looks to sell generics in China through joint venture with Guangzhou Pharma As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that as Teva has said it “has no agreement with...

May 25, 2017

Merck's Remicade discounting put squeeze on biosims—and broke U.K. law, officials say Under biosimilar assault in Europe, Merck rolled out cut-rate deals on Remicade to defend its brand from cheaper options, then-brand-new to the market. Now, the U.K.’s competition authority claims the pharma giant “broke competitio...

May 18, 2017

Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet One of AbbVie’s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a long way to go before they’ll really be able to celebrate. The U.S. Patent and Trademark Office’s Patent Trial and Appea...

Jul 18, 2014

On May 30, 2014, the U.S. Food and Drug Administration approved the first generic versions of Celebrex (celecoxib) capsules. Teva Pharmaceutical Industries received approval to market celecoxib capsules in 50 milligram, 100 mg, 200 mg, and 400 mg strengths, and has 180-day exclusivity on the 100 mg, 200 mg, and 400 ...